TRACON Pharmaceuticals Presents Data From Phase 1 Study Of Uliledlimab (TJ004309) And Tecentriq (Atezolizumab) At ASCO Meeting
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the
Alliance Global Partners Initiates Coverage On TRACON Pharmaceuticals with Buy Rating, Announces Price Target of $13
Alliance Global Partners initiates coverage on TRACON Pharmaceuticals (NASDAQ:TCON) with a Buy rating and announces Price Target of $13.
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.